1573 related articles for article (PubMed ID: 26621403)
1. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
Pedersen N
Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
[TBL] [Abstract][Full Text] [Related]
2. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
Elkjaer M
Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
[TBL] [Abstract][Full Text] [Related]
3. Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease.
Ankersen DV; Carlsen K; Marker D; Munkholm P; Burisch J
J Gastroenterol Hepatol; 2017 Mar; 32 Suppl 1():27-31. PubMed ID: 28244677
[TBL] [Abstract][Full Text] [Related]
4. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease.
Pedersen N; Elkjaer M; Duricova D; Burisch J; Dobrzanski C; Andersen NN; Jess T; Bendtsen F; Langholz E; Leotta S; Knudsen T; Thorsgaard N; Munkholm P
Aliment Pharmacol Ther; 2012 Nov; 36(9):840-9. PubMed ID: 22971016
[TBL] [Abstract][Full Text] [Related]
5. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Pedersen N; Thielsen P; Martinsen L; Bennedsen M; Haaber A; Langholz E; Végh Z; Duricova D; Jess T; Bell S; Burisch J; Munkholm P
Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002
[TBL] [Abstract][Full Text] [Related]
6. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet.
Maagaard L; Ankersen DV; Végh Z; Burisch J; Jensen L; Pedersen N; Munkholm P
World J Gastroenterol; 2016 Apr; 22(15):4009-19. PubMed ID: 27099444
[TBL] [Abstract][Full Text] [Related]
8. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
[TBL] [Abstract][Full Text] [Related]
9. Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease.
Carlsen K; Houen G; Jakobsen C; Kallemose T; Paerregaard A; Riis LB; Munkholm P; Wewer V
Inflamm Bowel Dis; 2017 Sep; 23(9):1473-1482. PubMed ID: 28617758
[TBL] [Abstract][Full Text] [Related]
10. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease.
Pedersen N; Ankersen DV; Felding M; Wachmann H; Végh Z; Molzen L; Burisch J; Andersen JR; Munkholm P
World J Gastroenterol; 2017 May; 23(18):3356-3366. PubMed ID: 28566897
[TBL] [Abstract][Full Text] [Related]
11. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
14. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment.
Elkjaer M; Burisch J; Avnstrøm S; Lynge E; Munkholm P
Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):695-704. PubMed ID: 19543101
[TBL] [Abstract][Full Text] [Related]
15. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
16. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
19. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
20. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
